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Abstract
Introduction Somatic inactivation of the TP53 gene in breast
tumors is a marker for poor outcome, and breast cancer
outcome might also be affected by germ-line variation in the
TP53 gene or its regulators. We investigated the effects of the
germ-line single nucleotide polymorphisms TP53  R72P
(215G>C) and MDM2 SNP309 (-410T>G), and p53 protein
expression in breast tumors on survival.
Methods We pooled data from four breast cancer cohorts
within the Breast Cancer Association Consortium for which
both TP53 R72P and MDM2 SNP309 were genotyped and
follow-up was available (n = 3,749). Overall and breast cancer-
specific survival analyses were performed using Kaplan-Meier
analysis and multivariate Cox's proportional hazards regression
models.
Results Survival of patients did not differ by carriership of either
germ-line variant, R72P (215G>C) or SNP309 (-410G>T)
alone. Immunohistochemical p53 staining of the tumor was
available for two cohorts (n = 1,109 patients). Survival was
worse in patients with p53-positive tumors (n = 301) compared
to patients with p53-negative tumors (n = 808); breast cancer-
specific survival: HR 1.6 (95% CI 1.2 to 2.1), P = 0.001. Within
the patient group with p53-negative tumors, TP53  rare
homozygous (CC) carriers had a worse survival than G-allele
(GG/GC) carriers; actuarial breast cancer-specific survival 71%
versus 80%, P = 0.07; HR 1.8 (1.1 to 3.1), P = 0.03. We also
found a differential effect of combinations of the two germ-line
variants on overall survival; homozygous carriers of the G-allele
in MDM2 had worse survival only within the group of TP53 C-
allele carriers; actuarial overall survival (GG versus TT/TG) 64%
versus 75%, P = 0.001; HR (GG versus TT) 1.5 (1.1 to 2.0), P
= 0.01. We found no evidence for a differential effect of MDM2
SNP309 by p53 protein expression on survival.
Conclusions The TP53 R72P variant may be an independent
predictor for survival of patients with p53-negative tumors. The
combined effect of TP53 R72P and MDM2 SNP309 on survival
is in line with our a priori biologically-supported hypothesis, that
is, the role of enhanced DNA repair function of the TP53 Pro-
variant, combined with increased expression of the Mdm2
protein, and thus overall attenuation of the p53 pathway in the
tumor cells.
ABCS: Amsterdam Breast Cancer Study; ER: estrogen receptor; HABCS: Hannover Breast Cancer Study; HEBCS: Helsinki Breast Cancer Study; 
HR: hazard ratio; SD: standard deviation; SEARCH: Studies of Epidemiology and Risk Factors in Cancer Heredity; TMA: tissue micro array.Breast Cancer Research    Vol 11 No 6    Schmidt et al.
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Introduction
Breast cancer outcome may be affected by germ-line variants
in genes that play a role in DNA damage control and repair
such as TP53 (R72P) and MDM2 (SNP309) [1,2]. The Mdm2
protein is a negative regulator of the tumor suppressor protein
p53 [3]. The R72P (215G>C) polymorphism of the TP53
gene is located in a proline-rich region of p53 suggested to be
required for the growth suppression activity of p53 [4] and for
its ability to induce apoptosis [5]. The two variant protein
forms, R72 (arginine) and 72P (proline), have been shown to
differ in their biological functions: the R72 variant is a stronger
and faster inducer of apoptosis than the 72P variant [6,7]. The
72P variant also binds more efficiently to iASPP, an inhibitor of
pro-apoptotic function of p53, which may be another reason
for the inferiority in apoptosis induction of this variant [8]. The
72P variant has been found to be more efficient in inducing
cell-cycle arrest [7] and DNA repair [9] than the R72 variant
which may protect tumor from chemotherapy-induced
apoptosis.
Previous studies have shown that the R72P polymorphism is
not associated with increased breast cancer risk [1,10,11].
However, an association of R72P with breast cancer survival
has been suggested, though with inconsistent results and
possibly only in patients with p53-negative tumors [10-16]. It
has also been suggested that patients with the Pro/Pro geno-
type are less sensitive to anthracycline-based treatment than
those with the Arg/Pro or Arg/Arg genotype [14,16], in line
with the Pro-allele being more efficient in cell-cycle arrest [7]
and DNA repair [9] induction.
A common single nucleotide polymorphism in the MDM2 pro-
moter region, a T to G change at nucleotide 309 in the first
intron (-410G>T; named SNP309), has been shown to create
an improved Sp1 binding site, leading to increased expression
of the Mdm2 protein and thus attenuation of the p53 pathway
and accelerated tumor formation in individuals carrying a
germ-line p53 mutation [17-19]. A number of small studies
revealed an inconsistent association between SNP309 and
breast cancer risk (see overview in [1], and [20,21]). However,
we have shown in a large pooled analyses of the Breast Can-
cer Association Consortium series that there is no general
association of SNP309 with breast cancer, nor if stratified by
estrogen receptor (ER) [1].
In two small studies no association between breast cancer
survival and MDM2  SNP309 genotype alone was found
[13,22]. However, the results of one of those studies sug-
gested a differential effect of MDM2 SNP309 genotype by
tumor p53 status (mutant p53 or aberrant protein expression)
on breast cancer survival [22]. Though MDM2 SNP309 has
been implicated to affect survival in other tumors (for example,
[23]), as far as we know there are no other publications on
breast cancer outcome and this polymorphism, except for a 
recent publication in BRCA1/2 carriers of Ashkenazi origin
[24]. Our aim was to investigate the combined effects of
MDM2 SNP309 and TP53 R72P polymorphisms and p53
protein expression on breast cancer survival.
Materials and methods
Clinico-pathologic data and genotyping
Breast cancer cases from four European studies within the
Breast Cancer Association Consortium were included in this
analysis (Table 1) [1,25]. Patients that were genotyped for
MDM2 SNP309 and TP53 R72P from studies with follow-up
data were included [1]. Patient selection criteria, participation
rates and information on the collection of follow-up and clinical
data are shown in Table 1. P53 protein expression data were
available for two of the four studies (Table 1). Immunohisto-
chemical staining of TMA slides was performed with a mouse
monoclonal anti-human p53-antibody (DO-7, DAKO) (Table
1). Missing p53 data could be attributed to missing tumor
blocks, loss of cores in the slicing or staining process or cores
not containing enough tumor material. P53 protein expression
scoring and MDM2  SNP309 and TP53  R72P genotyping
were performed blinded to the survival status of the patients.
Genotyping assays were performed by each group separately
[1] (see Table 1 for assay description). Primer (and probe)
sequences are available from the authors upon request. Meth-
ods and results in this paper are reported following the
REMARK recommendations [26]. All studies were approved
by the appropriate (Medical) Ethical Research Committees.
Statistical analyses
Univariate analyses of survival were performed by calculating
Kaplan-Meier survival curves and comparing subsets of
patients using log-rank test. To explore the effects of several
variables and their combined effects on survival, multivariate
Cox's proportional hazards regression models were used
(reported as Hazard Ratio (HR) with 95% confidence interval).
Results are reported for one polymorphisms stratified by the
other polymorphisms or p53 expression, adjusted for other
covariates. Interaction terms were tested by Cox regression
models including the main effects (2df each), interaction
terms, for example, four interaction terms for both polymor-
phisms, and other covariates. Covariates included were prog-
nostic factors for breast cancer survival, that is, age, stage,
grade and ER and p53 protein expression. In order to run mod-
els including all patients, missing value categories were
included for each separate variable with missing information.
Polymorphisms were included as categorical variables (with
the homozygous common allele group as reference), or as a
continuous variable in the per-allele analyses. All pooled anal-
yses were adjusted for study, that is, ABCS, HABCS, HEBCS,
SEARCH, included as a categorical variable. Breast cancer-
specific survival was defined as survival until death from breast
cancer, with breast cancer being the underlying cause of
death; death due to other causes was censored (these analy-Available online http://breast-cancer-research.com/content/11/6/R89
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ses included the ABCS and HEBCS studies, see Table 1).
Overall survival was defined as survival until death of any
cause. In all analyses, follow-up time was censored at 10
years. All statistical tests used were two-sided and P values <
0.05 were considered statistically significant. All analyses
were performed using SPSS 15.0 (SPSS Inc, Chicago, IL,
USA).
Results
Patient characteristics
Breast cancer patients with follow-up and TP53 R72P and
MDM2  SNP309 genotypes from three hospital-based and
one population-based study within the Breast Cancer Associ-
ation Consortium were included for analysis (n = 3,749)
(Table 1). Frequencies of TP53 R72P and MDM2 SNP309
and clinicopathologic characteristics of the breast cancer
patients in the four studies are shown in Table 2. We have
described and discussed earlier the small difference in MDM2
Table 1
Characteristics of the studies and genotyping assays
Contributing 
studies
Design Description of 
case subjects 
and 
ascertainment
(age range)
Participation 
rates
Follow-up P53 IHC* Genotyping 
platform(s) 
[38-40]
ABCS: 
Amsterdam Breast 
Cancer Study, The 
Netherlands [41]
Hospital-based 
consecutive cases
All operable 
breast cancer 
patients aged < 
50 years 
diagnosed 1974-
1994 in four 
Dutch hospitals 
(Amsterdam and 
Leiden) (23 to 50 
years)
All patients with 
paraffin-
embedded tissue 
blocks available 
(normal tissue) 
from the 
Pathology 
archives and 
successful DNA 
isolation 
(approximately 
85%)
Active follow-up 
through the 
medical registries 
and general 
practitioners
By IHC staining of 
TMAs* as 
previously 
described [25]; 
p53 positive 
defined as > 10% 
of cells with 
positive nuclear 
staining.
Taqman
HABCS: 
Germany:
Hannover Breast 
Cancer Study and 
bilateral breast 
cancer patients 
[42,43]
Hospital-based 
case-control 
studies
Case patients who 
received 
radiotherapy for 
breast cancer at 
Hannover Medical 
School between 
1997 and 2003 
(27 to 91 years)
Approximately 
80% of case 
subjects 
contacted agreed 
to give a blood 
sample
Active follow-up at 
the Department of 
Radiation 
Oncology, 
Hannover Medical 
School
NA Restriction 
enzyme-based 
assays
HEBCS:
Helsinki Breast 
Cancer Study 
[10,44]
Hospital-based 
case-control study
Consecutive 
incident cases 
from the 
Department of 
Oncology, 
Helsinki University 
Central Hospital 
1997-1998
(22 to 96 years)
79% of the case 
subjects
Active follow-up of 
the medical 
records until five 
years and annual 
linkage to the 
nation-wide 
Finnish Cancer 
Registry
By IHC staining of 
TMAs* as 
previously 
described [10] 
and data for 23 
cases derived 
from the pathology 
reports; p53 
positive defined as 
> 20% of cells 
with positive 
nuclear staining.
RFLP (MDM2 
SNP309)
Amplifluor(tm) 
fluorescent 
genotyping 
(Kbiosciences) 
(TP53 R72P)
SEARCH: Studies 
of Epidemiology 
and Risk Factors 
in Cancer 
Heredity, 
Cambridge, UK 
[45]
Population-based 
case-control study
Two groups of 
case patients 
(prevalent and 
incident) identified 
through East 
Anglian Cancer 
Registry: patients 
diagnosed before 
age 55 years in 
1991 to 1996 and 
still alive when 
study started in 
1996 and patients 
diagnosed before 
age 70 years 
since 1996 (25 to 
65 years)
64% of eligible 
case subjects 
provided a blood 
sample
Combination of 
passive follow-up 
through national 
death registrations 
and active follow 
up every five years 
by the cancer 
registry
NA Taqman
*IHC = immunohistochemistry; TMA = Tissue Micro Array; NA = not applicable (no p53 data available).Breast Cancer Research    Vol 11 No 6    Schmidt et al.
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Table 2
Germ-line variants and clinicopathologic characteristics of breast cancer patients by study
ABCS
N = 1076
HABCS
N = 152
HEBCS
N = 599
SEARCH
N = 1922
P value*
N% N% N% N%
MDM2 SNP309 TT 444 41.3 55 36.2 183 30.6 774 40.3
GT 487 45.3 73 48.0 311 51.9 913 47.5
GG 145 13.5 24 15.8 105 17.5 235 12.2 < 0.001
TP53 R72P GG 570 53.0 85 55.9 314 52.4 1052 54.7
GC 422 39.2 55 36.2 236 39.4 733 38.1
CC 84 7.8 12 7.9 49 8.2 137 7.1 0.9
Stage 1 341 31.9 83 69.2 205 36.9 861 52.4
2 581 54.4 36 30.0 295 53.1 713 43.4
3 146 13.7 1 0.8 56 10.1 69 4.2 < 0.001
Missing 83 2 4 3 2 7 9
Differentiation 
grade
1 338 35.8 9 8.7 138 24.6 368 25.4
2 317 33.6 55 53.4 243 43.2 647 44.7
3 288 30.5 39 37.9 181 32.2 431 29.8 < 0.001
Missing 133 49 37 476
ER status tumor Negative 240 34.2 18 15.4 135 23.2 175 19.8
Positive 461 65.8 99 84.6 446 76.8 708 80.2 < 0.001
Missing 375 35 18 1039
p53 status tumor Negative 473 70.4 335 76.7
Positive 199 29.6 102 23.3 0.02
Missing 404 152 162 1922
Vital status 
patient
Alive 694 64.5 129 84.9 462 77.1 1596 83.0
Deceased, all 382 35.5 23 15.1 137 22.9 326 17.0 < 0.001
Deceased, breast 
cancer
337 20 105
Years of 
diagnosis
Range 1974 to 1994 1997 to 2003 1997 to 1998 1991 to 1996
Age at diagnosis Mean ± SD 42.8 5.2 56.8 11.3 56.4 12.8 50.1 7.7 < 0.001
Follow-up Mean ± SD 10.5 5.7 6.5 1.9 7.3 2.1 6.3 2.1 < 0.001
* P value of comparison of either categories of non-missing data among studies (by chi-square) or comparison of continuous data (by t-test).Available online http://breast-cancer-research.com/content/11/6/R89
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SNP309 allele frequencies between European populations [1]
while difference in patient characteristics between studies can
mostly be attributed to differences in patient selection criteria
(Table 1). Mean follow-up was 7.7 years (SD 4). A small
number patients (n = 26) were carriers of the homozygous rare
variants for both polymorphisms (Table 3).
Breast cancer survival by TP53 R72P, MDM2 SNP309 
genotype, and p53 tumor status
Overall survival of patients did not differ by carriership of either
germ-line variant, R72P or SNP309, alone in the pooled anal-
yses (Table 4). Tumor p53 status was available for 1109
patients from the ABCS and HEBCS series (Table 1). In both
series, the patients with p53-positive tumors showed poorer
overall survival than the patients with p53-negative tumors
(pooled HR 1.5 (1.2-1.9), P = 0.002; Table 4).
Differential effect of TP53 R72P on breast cancer survival 
stratified for p53 tumor status
In the patient group with p53-negative tumors, the actuarial
breast cancer-specific survival for the patients carrying the
TP53 CC genotype (Pro/Pro) was worse, though not statisti-
cally significantly, at 10 years of follow-up as compared to
those carrying TP53 GG/GC (Arg/Arg; Arg/Pro) (71% versus
80% P = 0.07; Figure 1). The interaction terms between p53
expression and TP53 R72P were not significant in a multivari-
ate Cox regression analysis, but considering the difference
seen in the actuarial curves we still considered it useful to per-
form Cox analyses stratified for p53 expression. Patients with
the TP53 CC genotype had worse breast-cancer specific sur-
vival (HR adjusted for study, age, stage, grade and ER: 1.79
(1.05 to 3.05, P = 0.03) (Table 5). Results for overall survival
were in line with those of breast-cancer specific survival, but
did not reach statistical significance (P = 0.06, Table 5).
Within the patient group with p53-positive tumors, breast can-
cer-specific survival stratified by TP53 R72P seemed to show
inconsistent results between studies though none were signif-
icant, that is, per allele HR (adjusted for age, stage, grade and
ER) in the ABCS study was 0.74 (0.45 to 1.22) and in the
HEBCS study 1.46 (0.79 to 2.69). The pooled HR (adjusted
for study, age, stage, grade and ER) was 0.82 (0.53 to 1.27)
for heterozygous and 0.86 (0.34 to 2.18) for homozygous C-
allele carriers (Table 5). There was no evidence for a differen-
tial effect of MDM2 SNP309 by p53 tumor status on survival
(Table 5).
Combined effects of TP53 R72P and MDM2 SNP309 on 
breast cancer survival
MDM2 SNP309 showed a differential actuarial overall survival
stratified by TP53 R72P in the pooled analyses (n = 3,749),
that is, homozygous carriers of the G-allele in MDM2  had
worse survival within the group of TP53 GC carriers (GG:
65% versus GT: 72% and TT: 76%, P = 0.006; Figure 2). The
same trend was visible in the TP53 homozygous CC group (n
= 26 GG/CC), but this was not statistically significant. Within
the TP53 C-allele carriers combined, MDM2 GG carriers had
significantly worse survival compared to TT/TG carriers: 64%
versus 75%, P = 0.001. In multivariate analyses (adjusting for
study, age, stage, grade and ER) the interaction term for TP53
GC and MDM2 GG was significant (P = 0.028), also if addi-
tional interaction terms for TP53 R72P and p53 expression
were included (P = 0.027). The multivariate models (adjusting
for study, age, stage, grade and ER) stratified for TP53 R72P
(analogue to Figure 2) showed that MDM2 GG carriers had
significantly worse survival compared with MDM2 TT carriers
only within the TP53 C-allele carriers; more specifically, within
TP53 CG carriers: HR 1.43 (1.05 to 1.96), P = 0.02; within
TP53 CC carriers HR 1.39 (0.56 to 3.48), P = 0.48 (Table 6);
within TP53 CG and CC carriers combined: HR (adjusted for
study, age, stage, grade and ER) 1.46 (1.09 to 1.96), P =
0.01.
Discussion
In the survival analyses including 3,749 breast cancer patients
from Finland, The Netherlands, Germany and United Kingdom,
we showed combined effects of two germ-line polymor-
phisms, TP53 R72P, MDM2 SNP309, and p53 tumor expres-
sion (by immunohistochemistry). Firstly, we confirmed our
earlier observation in Finnish patients [10] that TP53 R72P
homozygous carriership predicts a worse survival in patients
with p53-negative tumors, also when adjusted for clinical
prognostic variables. Thus, in the absence of inactivating p53
mutations in the tumor, the 72P variant form of p53 protein
may have a compromising effect on the p53 apoptotic func-
tion, leading to reduced survival of the patients. Similarly, a
study of 414 Chinese breast cancer patients reported that the
72P homozygous (CC) genotype was associated with both
poorer five-year overall survival (five to eight percentile differ-
ence, P = 0.04) and poorer disease-free survival among the
patients with a wild-type p53 in their tumors (n = 346) [16]. In
line with other studies published we did not observe an effect
of carriership of R72P alone on survival of patients [12-16].
No significant difference in survival by TP53 R72P carriership
was observed among the patients with p53-positive tumors,
who showed a worse survival overall compared to p53-nega-
Table 3
Frequencies of TP53 R72P and MDM2 SNP309 germ-line 
variants
TP53 R72P GG GC CC
N%N%N%
MDM2 SNP309 TT 799 54.9 546 37.5 111 7.6
GT 940 52.7 699 39.2 145 8.1
GG 282 55.4 201 39.5 26 5.1Breast Cancer Research    Vol 11 No 6    Schmidt et al.
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Table 4
HR estimates of overall survival* by TP53 R72P, MDM2 SNP309 and p53
TP53 R72P** HR Lower and upper limit 95% CI P value
ABCS
GC 0.99 0.79 1.26 0.95
CC 0.72 0.45 1.16 0.17
HABCS
GC 1.40 0.60 3.45 0.46
CC 2.54 0.69 9.34 0.16
HEBCS
GC 1.17 0.82 1.67 0.40
CC 1.72 1.00 2.98 0.05
SEARCH
GC 1.18 0.95 1.49 0.14
CC 0.93 0.59 1.48 0.77
Pooled†
GC 1.11 0.96 1.28 0.18
CC 1.00 0.76 1.31 0.97
MDM2 SNP309**
ABCS
TG 0.93 0.73 1.18 0.54
GG 0.99 0.70 1.40 0.97
HABCS
TG 0.60 0.25 1.46 0.26
GG 0.36 0.08 1.65 0.19
HEBCS
TG 0.76 0.53 1.11 0.16
GG 0.91 0.56 1.47 0.69
SEARCH
TG 1.03 0.82 1.31 0.78
GG 1.43 1.03 1.97 0.03
Pooled†
TG 0.93 0.80 1.08 0.34
GG 1.11 0.90 1.37 0.31
p53 status tumor **
ABCS
p53 positive 1.31 0.96 1.80 0.09
HEBCS
p53 positive 1.93 1.27 2.94 0.002
Pooled†
p53 positive 1.50 1.16 1.93 0.002
Breast cancer-specific survival
Pooled†
p53 positive 1.57 1.20 2.05 0.001
*Overall survival including all studies unless otherwise specified; ** HRs of heterozygous and homozygous rare allele groups have been calculated 
by comparison to the reference categories of common alleles: TP53 R72P = GG; MDM2 SNP309 = TT; p53 = negative tumors; †Pooled 
analyses have been adjusted for study.Available online http://breast-cancer-research.com/content/11/6/R89
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tive tumors. In the pooled analysis, CC homozygote patients
with p53-positive tumors even tended to have a better survival.
In the study by Xu et al. in Chinese breast cancer patients [16],
the CC homozygote patients also had non-significant better
survival than the GG homozygotes and heterozygotes within
the group of patients with p53-mutated tumors.
The finding of CC homozygote (72P) carriers having poorer
survival is consistent with the R72 variant of wild-type p53
being a more potent inducer of apoptosis than the wild-type
72P variant. It has been suggested that R72 homozygotes
may respond more favorably to radiation or chemotherapy
[27]. Response rate after chemo-radiotherapy of advanced
squamous cell carcinomas of head and neck and survival was
higher in patients with the R72 allele compared to those with
the 72P allele [28]. These favorable effects of the R72 allele
may, however, be reversed by a somatic p53 mutation on this
allele, as has been reported in squamous cell carcinomas of
head and neck [29,30]. In line with this, retention of the R72
allele with loss of the 72P allele in the tumor tissue has been
associated with reduced survival in heterozygous breast can-
cer patients [31].
Carriership of MDM2 SNP309 alone did not affect survival of
patients in our study and two other, smaller studies [13,22].
However, we found an 11 percentile survival difference for
homozygous MDM2 G-allele carriers within the group of TP53
C-allele (72P) carriers. Biologically this seems plausible con-
sidering the reduced apoptotic function of the TP53 Pro-vari-
ant [6,7] and the attenuation of the p53 pathway by mdm2, the
production of which is increased by the SNP309 G-variant
[17]. In addition, the interaction of both polymorphisms
remained statistically significant in multivariate models adjust-
ing for clinical prognostic factors.
We did not observe evidence for a combined effect of
SNP309 and p53 tumor expression (as shown here by results
of SNP309 stratified by p53 status in Table 5, but obviously
p53 did also not have a differential effect on survival stratified
by SNP309). This is in contrast to a previous, smaller study (n
= 248) in the American population, which suggested that
tumor p53 status was associated with breast cancer survival
only among patients homozygous for the MDM2 SNP309 T-
allele and not among carriers of the variant G-allele [22].
Though our study is one of the largest published studies on
combined effects of the germline genetic variation and tumor
somatic events, the numbers are still small for looking at such
modifying effects on survival.
Many studies have confirmed that mutated p53 is a prognostic
factor in breast cancer. The risk of dying of breast cancer for
patients with a p53 mutation in their tumor has been estimated
to be two to five-fold compared to patients with wild-type p53
tumors [32,33]. Positive immunostaining for p53 is in general
considered to indicate somatic p53 mutation and an impaired
p53 pathway, though the correlation with TP53 mutations is
incomplete [34,35]. The accumulation of p53 in the tumors
detected by immunohistochemistry was a prognostic marker
of poorer survival in both our series with p53 immunohisto-
chemistry data available (the HEBCS and ABCS series). This
effect was somewhat stronger in the HEBCS series, which
may be explained by the more stringent cut-off used (20%
positive tumor cells compared to 10% in the ABCS series).
Conclusions
We have shown here that TP53 R72P may have additional
prognostic value especially among patients with p53-negative
tumors. However, the effect of p53 on outcome may be influ-
enced by adjuvant systemic therapy (for example, [31,36],
reviewed in Bertheau [37]) and larger studies will be needed
to address this question. Our study is one of the few that have
shown an interaction of germ-line variants, that is, TP53 R72P
and MDM2 SNP309, in breast cancer survival. The results,
showing a statistically significant interaction of the p53 Pro-
variant and the GG genotype of MDM2 SNP309, are in line
with our a priori biologically-supported hypothesis, which is,
the role of enhanced DNA repair function of the Pro-variant,
combined with increased expression of the Mdm2 protein, and
thus overall attenuation of the p53 pathway in the tumor cells.
These results suggest that even subtle differences in p53
apoptotic function caused by synergistic polymorphisms may
affect patient's survival, possibly by modifying treatment
response. Altogether, our findings are in line with biological
evidence in literature, and in the future, may have also clinical
significance for models of breast cancer prognosis or treat-
ment. However, because this is the first report on the com-
Figure 1
Cumulative breast cancer-specific survival (Kaplan Meier) of breast  cancer patients with p53 negative tumors stratified by TP53 R72P Cumulative breast cancer-specific survival (Kaplan Meier) of breast 
cancer patients with p53 negative tumors stratified by TP53 R72P. 
Survival in the TP53 CC group was worse compared to that in the GC 
and GG group combined (80% versus 71%, P = 0.07).Breast Cancer Research    Vol 11 No 6    Schmidt et al.
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Table 5
HR estimates of overall and breast cancer-specific survival by TP53 R72P, in p53 negative and positive tumors (multivariate models)
TP53 R72P HR Lower and upper limit 95% CI P value
Overall survival
p53 negative tumors
GC 1.11 0.80 1.52 0.54
CC 1.63 0.97 2.74 0.06
p53 positive tumors
GC 0.82 0.53 1.27 0.37
CC 0.86 0.34 2.18 0.75
Breast cancer-specific survival
p53 negative tumors
GC 0.97 0.68 1.37 0.85
CC 1.79 1.05 3.05 0.03
p53 positive tumors
GC 0.90 0.57 1.42 0.65
CC 1.00 0.39 2.55 1.00
MDM2 SNP309 HR Lower and upper limit 95% CI P value
Overall survival
p53 negative tumors
TG 0.84 0.60 1.17 0.30
GG 1.28 0.85 1.94 0.24
p53 positive tumors
TG 0.78 0.49 1.24 0.30
GG 0.78 0.41 1.48 0.45
Breast cancer-specific survival
p53 negative tumors
TG 0.92 0.64 1.31 0.63
GG 1.41 0.90 2.19 0.13
p53 positive tumors
TG 0.76 0.47 1.23 0.27
GG 0.69 0.35 1.39 0.30
Pooled analyses for studies with p53 information (ABCS and HEBCS); HRs of heterozygous and homozygous rare allele groups have been 
calculated by comparison to the reference categories of the homozygous common allele: TP53 R72P = GG, and MDM2 SNP309 = TT; analyses 
have been adjusted for study, age, stage, grade and ER.Available online http://breast-cancer-research.com/content/11/6/R89
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Figure 2
Cumulative overall survival of breast cancer patients by MDM2 SNP309 and TP53 R72P genotypes Cumulative overall survival of breast cancer patients by MDM2 SNP309 and TP53 R72P genotypes. Each figure shows Kaplan Meier survival 
curves of MDM2 SNP309 genotypes within one group of TP53 R72P genotype. (a) TP53 GG genotype (ns); (b) TP53 GC genotype (P = 0.006); 
(c) TP53 CC genotype (ns). The numbers at start of follow-up were: Figure A: TT n = 798, TG n = 939, GG n = 281; B: TT n = 545, TG n = 698, 
GG n = 200; C: TT n = 110, TG n = 144, GG n = 25. Within the TP53 C-allele carriers (Figure A and B combined), MDM2 GG carriers had signif-
icantly worse survival compared to TT/TG carriers combined: 64% versus 75%, P = 0.001.Breast Cancer Research    Vol 11 No 6    Schmidt et al.
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bined effect of TP53 R72P and MDM2 SNP309 on breast
cancer survival and we cannot exclude a chance finding, other
studies to confirm this will be necessary. Larger studies will be
needed also to investigate the effect of specific treatment
modalities on the survival by TP53 R72P and MDM2 SNP309.
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